Fulcrum Therapeutics falls after scrapping sickle cell drug development
BUZZ-Fulcrum Therapeutics falls after scrapping sickle cell drug development ** Shares of drug developer Fulcrum Therapeutics FULC.O fall about 49% to $3.28 after the bell
** Co says it is discontinuating development of its experimental pociredir program for the treatment of sickle cell disease, an inherited blood disorder
** Adds will explore potential strategic alternatives, including, but not limited to, a merger, acquisition, business combination, or other strategic transactions involving the company or its assets
** Says FDA raised concerns regarding pociredir's benefit-risk profile in SCD, stemming from an unexpectedly high rate of secondary hematologic malignancies observed with Ipsen's IPN.PA drug called Tazverik which was recently withdrawn from the global market
** Co has initiated efforts to significantly reduce its operating expenses and preserve capital
** As of March 31, 2026, Fulcrum had $333.3 million in cash, cash equivalents, and marketable securities
** FULC down 43% YTD
(Reporting by Sriparna Roy in Bengaluru)
Recent news on Ipsen SA
See all newsFulcrum falls after discontinuing sickle cell drug program
Fulcrum falls after discontinuing sickle cell drug program
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics falls after scrapping sickle cell drug development
Brief: Ipsen's IQIRVO Shows Meaningful Fatigue Improvements In Moderate-To-Severe PBC Patients